昕泰治疗多发性骨髓瘤的有效性及安全性研究

Efficacy and Safety of XinTai~? in the Treatment of Multiple Myeloma

目的:探讨以昕泰为主的化疗方案治疗多发性骨髓瘤的临床疗效及不良反应。方法:选取我院血液内科2018年1月～2018年4月收治的29例多发性骨髓瘤患者,按用药不同分为昕泰组(国产硼替佐米)和万珂组(进口硼替佐米),分析两组的疗效及不良反应。结果:昕泰组和万珂组的平均治疗疗程数分别为2.2和2.0,总有效率(ORR)分别为86.67%和85.71%,完全缓解率(CR)分别为13.33%和21.43%,均无统计学差异(均P>0.05)。昕泰组神经毒性作用(6.67%)低于万珂组(28.57%),但差异无统计学意义(P>0.05)。3例肾功能不全患者,其中昕泰组1例,万珂组2例,治疗2个疗程后肾功能均逆转。结论:国产硼替佐米(昕泰)在治疗多发性骨髓瘤中,临床有效性及安全性与进口硼替佐米(万珂)相当。

Objective:To investigate the clinical efficacy and adverse effects of XinTai~?-based chemotherapy in the treatment of multiple myeloma.Methods:Twenty-nine patients with multiple myeloma were enrolled in the department of hematology from January 2018 to April 2018.They were divided into XinTai~?group(domestic bortezomib)and Velcade~?group(imported bortezomib).The efficacy and safety of the two groups were retrospectively analyzed.Results:The mean number of treatment courses in XinTai~?group and Velcade~?group were 2.2 and 2.0,respectively.The overall response rate(ORR)was 86.67%and 85.71%in XinTai~?group and Velcade~?group,with complete remission(CR)rate of 13.33%and 21.43%,respectively(all P>0.05).The rate of peripheral neuropathy was 6.67%in XinTai~?group,which was lower than that of Velcade~?group(28.57%),with no statistically significant difference(P>0.05).There were 3 cases of renal insufficiency,including 1case in XinTai~?group and 2 cases in Velcade~?group,whose renal function were all reversed after 2 courses of treatment.Conclusion:The efficacy and safety of XinTai~?are comparable to that of Velcade~?in the treatment of multiple myeloma.